Sumitovant Biopharma Ltd. has officially acquired Myovant Sciences Ltd. The deal was originally announced October 23, 2022.
Neochromosome and Sumitovant Biopharma Announce Successful Collaboration to Accelerate Protein Drug Discovery and Improve Manufacturing
Two Sumitovant Biopharma entities are merging under one name, effective immediately.
Shares of Myovant Sciences rose in premarket trading Monday after the company agreed to be acquired by Sumitovant Biopharma for $2.9 billion - three weeks after turning down a previous offer.
BASEL, Switzerland, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences Ltd. (NYSE: MYOV) (the “Company”) confirmed today that it has received a preliminary, non-binding proposal (the “Proposal”) from Sumitovant Biopharma Ltd. (“Sumitovant”) and Sumitomo Pharma Co., Ltd. (collectively with Sumitovant, “Sumitomo”) to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75 per share in cash. Sumitovant currently holds approximately 52% of the outstanding shares of the Company.
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the peer-reviewed journal publication of the findings from a survey of Directors of Nursing (DONs) in U.S. long-term care settings. The results highlight the need for improved awareness, education, and management of urinary incontinence (UI) related to overactive bladder (OAB) in the long-term care population.
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., announced new analyses from the Phase 3 EMPOWUR Extension Study of GEMTESA, presented Sunday at the 2022 annual meeting of the American Urological Association (AUA2022). The meeting is being held in New Orleans from May 13-16, 2022.
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-blind, placebo-controlled exploratory study of URO-902, an investigational, novel, locally injected gene therapy product (plasmid human cDNA encoding maxi-K channel), in patients with overactive bladder (OAB), who were not well managed by oral therapies
LONDON and NEW YORK, February 10, 2022 — Sumitovant Biopharma Ltd., in partnership with its parent company Sumitomo Dainippon Pharma Co., Ltd., recently announced the launch of a phase 1 study in the U.S. on a new drug candidate (“KSP-1007”) for carbapenem-resistant bacterial infections. The launch is a result of a joint research project between Sumitomo Dainippon Pharma and the Kitasato Institute in Japan. Sumitovant is leading the program of the compound in the U.S. targeting complicated urinary tract and intra-abdominal infections.
Class is dismissed for PharmStars’ first cohort of digital health startup companies. The pharma-focused accelerator recently graduated 12 companies after a 10-week educational program and a final showcase meet-up with six pharma members – Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sumitovant Biopharma, Takeda and Alexion (now part of AstraZeneca).